Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kestra Medical Technologies Ltd. ( (KMTS) ) just unveiled an announcement.
On June 4, 2025, Kestra Medical Technologies Ltd. announced the election of Mr. Conor Hanley to its Board of Directors, highlighting his extensive leadership experience in the medical technology sector. Additionally, the company amended employment agreements with key executives, redefining ‘Good Reason’ for termination, which could impact executive stability and company operations.
The most recent analyst rating on (KMTS) stock is a Buy with a $27.00 price target. To see the full list of analyst forecasts on Kestra Medical Technologies Ltd. stock, see the KMTS Stock Forecast page.
Spark’s Take on KMTS Stock
According to Spark, TipRanks’ AI Analyst, KMTS is a Underperform.
Kestra Medical Technologies Ltd.’s stock score is primarily impacted by its strong revenue growth, but this is overshadowed by significant financial challenges, including negative equity and ongoing cash flow issues. Technical analysis provides a slight positive note with short-term momentum, but valuation concerns due to a negative P/E ratio weigh heavily. The absence of earnings call data and significant corporate events means these factors do not influence the score.
To see Spark’s full report on KMTS stock, click here.
More about Kestra Medical Technologies Ltd.
Kestra Medical Technologies Ltd. operates in the medical technology industry, focusing on innovative healthcare solutions. The company provides products and services aimed at enhancing patient care and medical outcomes.
Average Trading Volume: 189,548
Current Market Cap: $1.02B
Learn more about KMTS stock on TipRanks’ Stock Analysis page.